Cargando…
Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Positioning within the framework of the SARS-CoV-2 (COVID-19) pandemic()
The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. COVID-19 affected close to 2 million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019. The relation of the disease cause...
Autores principales: | Miranda-Zazueta, G., González-Regueiro, J.A., García-Juárez, I., Moctezuma-Velázquez, C., López-Díaz, F.J., Pérez-González, B., Uscanga-Domínguez, L.F., Peláez-Luna, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832058/ http://dx.doi.org/10.1016/j.rgmxen.2020.06.002 |
Ejemplares similares
-
Manejo farmacológico de pacientes con enfermedades hepáticas y pancreáticas que involucran terapias inmunosupresoras. Posicionamiento en el marco de la pandemia de SARS-CoV-2 (COVID-19)
por: Miranda-Zazueta, G., et al.
Publicado: (2020) -
Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis
por: Devogelaere, Jens, et al.
Publicado: (2020) -
Prioritizing SARS-CoV-2 testing in a highly immunosuppressed patient population
por: Shackelford, Jenna, et al.
Publicado: (2022) -
Immunogenicity and Safety of Standard and Third‐Dose SARS–CoV‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
por: Syversen, Silje W., et al.
Publicado: (2022) -
Predicting Coronavirus Disease 2019 Infection Risk and Related Risk Drivers in Nursing Homes: A Machine Learning Approach
por: Sun, Christopher L.F., et al.
Publicado: (2020)